Skip to main content
CGON logo

CGON · CG Oncology, Inc.

Track CGON — free
$80.47 -1.44 (-1.75%)
Market Cap
$7.32B
Shares
89.32M
Volume · Nov 20 607.54K Avg daily vol (3M) 1.21M

Price & Indicators

 

Key stats

Close
$81.90
Thu 19 Nov
Open
$84.03
Thu 19 Nov
Average volume, 30 days
1.6M
shares a session
Short interest
9.2M
10.3% of shares · 11.0 days to cover
Day range
$79.96$84.22
Open $84.03 Close $81.90
52-week closing range
$37.37$84.78
Close $81.90 3.4% under the high
Short volume, last session
51%
Latest filing
10-Q · Nov 6
Price history
Jan 2024 to Nov 2026

Latest documents

2026
Nov 16
Current report 8-K
PIVOT-006 cuts recurrence risk 68% in bladder cancer

CG Oncology reported that PIVOT-006 met its primary endpoint, with cretostimogene reducing recurrence risk by 68% (hazard ratio 0.32; 95% CI: 0.23, 0.45; p<0.0001). BLAs are planned for March 2027 and the second quarter of 2027.

Regulation FD disclosure, Other events
4 source passages
CG Oncology, Inc. (NASDAQ: CGON) today announced positive topline results from PIVOT-006, its Phase 3 registrational trial evaluating adjuvant intravesical cretostimogene grenadenorepvec in patients with intermediate-risk and high-grade Ta ≤3 cm NMIBC, following complete tumor resection. Cretostimogene resulted in a 68% reduction in the risk of recurrence compared with the control arm, with a hazard ratio of 0.32 (95% CI: 0.23, 0.45; p<0.0001). The Company anticipates completing the submission of its BLA for the use of cretostimogene to treat patients with BCG-unresponsive NMIBC with carcinoma in situ ("CIS") with or without papillary tumors, which will now also include BCG-unresponsive high-grade papillary-only disease (without CIS), in March 2027. The Company also plans to submit a BLA for the use of cretostimogene in intermediate-risk and high-grade Ta NMIBC in the second quarter of 2027. Open the document at this passage
Nov 6
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Net loss widens as R&D spending accelerates

CG Oncology reported a $196.1 million net loss for the nine months ended September 30, 2026, up from $119.7 million, as R&D expenses increased to $137.6 million. Cash, cash equivalents and marketable securities totaled $984.5 million.

Revenue $1.6M ▼ 3.7% Net loss $56.89M Diluted EPS -$0.64
Read from the MD&A section
3 source passages
Our net losses were $196.1 million and $119.7 million for the nine months ended September 30, 2026 and 2025, respectively. R&D expenses were $137.6 million for the nine months ended September 30, 2026 compared to $86.7 million for the nine months ended September 30, 2025. As of September 30, 2026, we had cash, cash equivalents and marketable securities of $984.5 million. Open the document at this passage
Nov 6
Current report 8-K
PIVOT-006 topline data expected in November 2026

CG Oncology reported a $56.9 million third-quarter net loss and expects PIVOT-006 Phase 3 topline data in November 2026, with $984.5 million in cash funding operations through 2029.

Financial results
3 source passages
PIVOT-006 (intermediate-risk and high-grade Ta ≤ 3cm NMIBC): Phase 3 topline data November 2026 Net Loss: Net loss was $56.9 million, or $(0.64) per share, for the third quarter of 2026, as compared to a net loss of $43.8 million, or $(0.57) per share, for the prior year period. Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2026 were $984.5 million, compared with $1.0 billion as of June 30, 2026. The Company anticipates its existing cash, cash equivalents and marketable securities as of this date will be sufficient to fund operations through 2029. Open the document at this passage
Aug 6
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $1.16M Net loss $79.06M Diluted EPS -$0.90
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$6.17M
Trailing 12 months
Net income (TTM)
−$237.46M
Trailing 12 months
Revenue growth YoY
-3.7%
Year over year
Operating margin
-4,293.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-2.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$981.46M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+15.8%
Year over year · more shares
Price change (1Y)
+92.3%
Trailing year
Short interest
10.3%
Latest settlement · 11.0 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +22%
above
Price vs 50-day avg +19%
above
RSI (14) 65
neutral
MACD trend Positive
52-week position 94%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +31%
trailing
6-month return +38%
trailing
YTD return +97%
this year
Relative strength +44%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $69 › 200d $67 — 50d above 200d
Institutional flow Flat
0% holders QoQ · +36 funds added
Insider flow Accumulating
Net +$2.7M over 90 days · 0% sells
Short interest Rising
10.32% of shares out · ▲ +3.9% MoM · 11.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
237 holders — near 3-yr high, broad support
Squeeze score 99
high risk · 0–100
Fundamentals
Weak
Revenue growth +255%
Y/Y
EPS growth −48%
Y/Y
Free cash flow $-132.5M
Quant / Vol
risk profile
Very High
Volatility 60%
annualized · 1-yr
Max drawdown −27%
past year
ATR 7.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 3 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+22% Bullish
Price vs 50-day avg
+19% Bullish
RSI (14)
65 Neutral
MACD trend
Positive Bullish
52-week position
94% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $69 › 200d $67 — 50d above 200d
Institutional flow Flat
0% holders QoQ · +36 funds added
Insider flow Accumulating
Net +$2.7M over 90 days · 0% sells
Short interest Rising
10.32% of shares out · ▲ +3.9% MoM · 11.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
237 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $37 Now $82 · 94% Range high $85
vs 200-day avg +22% vs 50-day avg +19%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CGON
CG Oncology, Inc.
this stock
$7.32B +97.3% +254.7% — 10.3%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
237
% held
104.1%
Net QoQ
-817.9K sh
Top holder
RTW INVESTMENTS, LP
Held Float
View
Held by Funds
Fund positions
331
View
Short & Settlement
Short Interest Rising
Shares short
9.2M
Days to cover
11.0d
Change
+342.7K sh
View
Short Volume
Short vol %
51%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
160
Value
$11.7K
As of
Sep 24, 2026
View
Off-Exchange
Off-exchange %
41.7%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$2.7M
Buyers / Sellers
2 / 0
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-161.0M
EPS diluted
$-2.08
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 16, 2026
This year
22

CG Oncology reported that PIVOT-006 met its primary endpoint, with cretostimogene reducing recurrence risk by 68% (hazard ratio 0.32; 95% CI: 0.23, 0.45; p<0.0001). BLAs are planned for March 2027 and the second quarter of 2027.

View
Proposed Sales
Value
$185.5K
Shares
3.0K
Filed
Oct 15, 2026
View
Earnings & Events
Webcasts
Last webcast
Sep 14, 2026
View
Investor Relations
Latest news
CG Oncology Reports Third Quarter…
Published
Nov 6, 2026
View

Performance

5D 20D 120D MTD YTD
CGON +16.8% +31.0% +38.3% +26.6% +97.3%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +22.2% +37.3% +43.9% +31.9% +92.3%
Key facts CIK 1991792 CUSIP 156944100 13F (30d) 239 filings 224 filers Visit website Investor relations